RLMD
$6.40+0.22 (+3.56%)
Relmada Therapeutics, Inc.
Historical Price
Peer Comparison
Whystock Valuation Model
Fundamentals
Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company in the United States. The company focuses on the development of NDV-01, a controlled-release intravesical formulation of gemcitabine and docetaxel, which is in Phase 2 clin...
Recent News
Why Relmada Therapeutics (RLMD) Is Up 38.8% After $160M Raise And Positive NDV-01 Phase 2 Data
Relmada Therapeutics recently reported past 12‑month interim Phase 2 data for NDV-01 in high-risk non-muscle invasive bladder cancer, showing strong complete response rates and a favorable safety profile, and has secured an oversubscribed US$160,000,000 private placement to support advancement into the Phase 3 RESCUE registrational program. The participation of prominent healthcare investors and the prospect of moving NDV-01 into late-stage trials highlight how clinical and financing...
A Look At Relmada Therapeutics (RLMD) Valuation After NDV-01 Phase 2 Update And US$160 Million Private Placement
Relmada Therapeutics (RLMD) is back in focus after releasing 12 month interim Phase 2 data for NDV-01 in high risk non muscle invasive bladder cancer, alongside a roughly US$160 million oversubscribed private placement. See our latest analysis for Relmada Therapeutics. The 1 day share price return of 61.1% to US$7.17, alongside a 30 day share price return of 84.8% and very large 1 year total shareholder return, suggests momentum has accelerated sharply as the NDV-01 data and US$160m private...
50% and 61% Gains in a Single Day: Why XENE and RLMD Soared Today
Two small-cap biotech names made serious noise today. Xenon Pharmaceuticals (XENE) is trading at $62.76, up 49.6% today, while Relmada Therapeutics (RLMD) sits at $7.17, also up 61.1% Both moves were absolutely eye-popping, but follow major news that has led investors to re-rate each stock. Clinical data results point to a brighter future ahead for both Xenon ... 50% and 61% Gains in a Single Day: Why XENE and RLMD Soared Today
Top Midday Gainers
Relmada Therapeutics (RLMD) said Monday it has struck a deal to sell shares and pre-funded warrants
Arcellx initiated, Cummins upgraded: Wall Street's top analyst calls
Arcellx initiated, Cummins upgraded: Wall Street's top analyst calls